Non-AlcoholicSteatohepatitis(NASH) is one of the emerging common liver diseases and is often referred to as a silent liver disease. The main feature that characterizes NASH from the entire spectrum of NAFLD is the accumulation of fat leading to major progression of disease towards cirrhosis which is generally diagnosed at the later stages.
As per the American Association for the Study of Liver Disease (AASLD), the annual clinical burden of NAFLD is projected to be substantial in both the United States and the Europe 4. In the United States, over 12 million incident cases of NAFL and over 600,000 incident cases of NASH are predicted, with proportionally similar results in Europe.
The Global NASH market is expected to reach USD 2,4036 USD million in 2024 in seven major markets including the US, EU5,and Japan. United States accounts for the largest share of the market, which accounts for approximately 46.1 percent followed by EU5 countries and Japan in 2016 owing to the highest prevalent cases, increasing research activities and improved healthcare resources. There is no approved marketed drug yet. Most of the supportive therapies available therapies are contributing to the largest share of the market. The global NASH market is expected to show an extensively significant growth in the near future owing to the rising prevalence of obesity, lifestyle changes, cardiovascular diseases etc.
Emerging drugs such as Ocaliva, Elafibranor, Cenicriviroc, Selonsertib are expected to get launched in 2023, 2022,2020 respectively shall fuel the market growth. Apart from the rising incidence of prevalent cases, obese population other factors like increased healthcare costs, increased GDP per capita are some of the growth drivers will fuel the market in near future. NASH market is obvious to encounter some of the major challenges like diagnostic challenges, complicated disease etiology and less awareness among the masses.
Some of the key players of the market are Intercept, Galmed Pharmaceuticals, Genfit, Allergan, Intercept and Gilead Sciences, which are exclusively involved in the NASH market. Hence, the report covers the in-depth analysis of NASH market along with current trends and comprehensive analysis of all the geographical regions. Also, the profile and growth of major key players are thoroughly analyzed in order to understand the competitive outlook of the global market.
Key Questions Answered:
- Prevalent cases of NASH Disease in the US, EU5,and Japan; 2016-2024
- Sub-type specific prevalent cases of NASH Disease in the US, EU5,and Japan; 2016-2024
- Diagnosed cases of NASH Disease in the US, EU5,and Japan; 2016-2024
- Market size of NASH Disease in the US, EU5,and Japan; 2016-2024
- Therapy wise market size of NASH Disease in the US, EU5,and Japan; 2016-2024
- Product Profile of Current Therapies: Elafibranor, Cenicriviroc, Selonsertib, Obeticholic acid
- Drug analysis of NASH Disease
- Pipeline product analysis of NASH Disease
- Detailed analysis of growth drivers, and challenges
- Detailed Company Profiling of Key Market Players: Gilead, Intercept, Allergan, Galmed, and Genfit
1. Executive Summary
2. NASH: Overview
I. Signs and Symptoms
II. Histologic and risk factors for NAFLD
III. Progression of NASH
IV. NASH Grading and Staging
V. Etiology
VI. Insulin Resistance
VII. Nash Etiology
VIII. Pathophysiology
IX. Internal Liver Signals
X. Complications
3. Diagnosis
I. Scoring Systems for NASH
II. Scheuer and Modified Laennec Scoring System
III. Modified Laennec Scoring System
4. Diagnostic Guidelines
I. AALD; ASG; AGA: NASH Diagnostic Recommendation
II. EASL, EASD, EASO: NASH Diagnostic Recommendation
5. Treatment
I. PPAR Agonists (Peroxisome proliferator?activator receptors)
II. FXR Bile Acid Axis
III. Lipid Altering Agents
IV. Incretin-based Therapies
V. Agents targeting inflammation, cell injury or death (apoptosis) and oxidative stress
VI. Gut and Microbiome related therapies
VII. Antifibrotic Therapies
6. Treatment Guidelines
I. EASL, EASD, EASO: NASH Treatment Recommendation
II. Japanese Society of Gastroenterology: Treatment Guidelines
III. Practical Guidelines by Japanese Society of Gastroenterology
7. Epidemiology
I. United States
a. Prevalent Cases of NASH
b. Sub-type Specific Prevalent Cases of NASH
c. Diagnosed Cases of NASH
II. Germany
a. Prevalent Cases of NASH
b. Sub-type Specific Prevalent Cases of NASH
c. Diagnosed Cases of NASH
III. France
a. Prevalent Cases of NASH
b. Sub-type Specific Prevalent Cases of NASH
c. Diagnosed Cases of NASH
IV. United Kingdom
a. Prevalent Cases of NASH
b. Sub-type Specific Prevalent Cases of NASH
c. Diagnosed Cases of NASH
V. Spain
a. Prevalent Cases of NASH
b. Sub-type Specific Prevalent Cases of NASH
c. Diagnosed Cases of NASH
VI. Italy
a. Prevalent Cases of NASH
b. Sub-type Specific Prevalent Cases of NASH
c. Diagnosed Cases of NASH
VII. Japan
a. Prevalent Cases of NASH
b. Sub-type Specific Prevalent Cases of NASH
c. Diagnosed Cases of NASH
8. Market Size of NASH
I. United States
a. Market Size of NASH
b. Therapy wise market Size of NASH
II. EU5
III. Germany
IV. France
V. United Kingdom
VI. Spain
VII. Italy
9. Japan
10. Pipeline Product Analysis
I. Elafibranor
II. Cenicriviroc
III. Selonsertib
IV. Obeticholic Acid
11. Growth Drivers
I. Rising Prevalent Cases
II. Rising Incident of Obese and Diabetic Population
III. Increased Healthcare Costs
IV. Increasing GDP per capita
V. Unmet Needs
12. Trends
I. Increased Research and Development
II. Development of NASH Diagnosis Methods and Biomarker
13. Challenges
I. Understanding Disease Pathogenesis
II. Diagnostic Challenges
14. Company Profiles
15. Gilead
I. Business Overview
II. Financial Overview
III. Product Overview
16. Intercept
I. Business Overview
II. Financial Overview
III. Product Overview
17. Allergan
I. Business Overview
II. Financial Overview
III. Product Overview
18. Galmed Pharmaceuticals
I. Business Overview
II. Financial Overview
III. Product Overview
19. Genfit
I. Business Overview
II. Financial Overview
III. Product Overview
20. About EffeMarket
21. Disclaimer
22. Contact US
Figure 1: NAFLD Spectrum
Figure 2: NASH Etiology via insulin resistance mechanism
Figure 3: Pathophysiology of NASH
Figure 4: Complications of NASH
Figure 5: Diagnostic Algorithm for NASH
Figure 6: EASL, EASD and EASO Diagnostic Algorithm and Follow up for NASH
Figure 7: Prevalent Cases of NASH in the United States (2016-2024)
Figure 8: Sub-type Specific Prevalent Cases of NASH in the United States (2016-2024)
Figure 9: Diagnosed Cases of NASH in the United States (2016-2024)
Figure 10: Prevalent Cases of NASH in Germany (2016-2024)
Figure 11: Sub-type Specific Prevalent Cases of NASH in Germany (2016-2024)
Figure 12: Diagnosed Cases of NASH in Germany (2016-2024)
Figure 13: Prevalent Cases of NASH in France (2016-2024)
Figure 14: Sub-type Specific Prevalent Cases of NASH in France (2016-2024)
Figure 15: Diagnosed Cases of NASH in France (2016-2024)
Figure 16: Prevalent Cases of NASH in the United Kingdom (2016-2024)
Figure 17: Sub-type Specific Prevalent Cases of NASH in the United Kingdom (2016-2024)
Figure 18: Diagnosed Cases of NASH in the United Kingdom (2016-2024)
Figure 19: Prevalent Cases of NASH in Spain (2016-2024)
Figure 20: Sub-type Specific Prevalent Cases of NASH in Spain (2016-2024)
Figure 21: Diagnosed Cases of NASH in Spain (2016-2024)
Figure 22: Prevalent Cases of NASH in Italy (2016-2024)
Figure 23: Sub-type Specific Prevalent Cases of NASH in Italy (2016-2024)
Figure 24: Diagnosed Cases of NASH in Italy (2016-2024)
Figure 25: Prevalent Cases of NASH in Japan (2016-2024)
Figure 26: Sub-type Specific Prevalent Cases of NASH in Japan (2016-2024)
Figure 27: Diagnosed Cases of NASH in Japan (2016-2024)
Figure 28: 7 Major Market Size of NASH, In USD Million (2016-2024)
Figure 29: Market Size of NASH in the United States, in USD Million (2016-2024)
Figure 30: Therapy Wise Market Size of NASH in the United States, in USD Million (2016-2024)
Figure 31: EU5 Market Size of NASH, in USD Million (2016-2024)
Figure 32: Market Size of NASH in Germany, in USD Million (2016-2024)
Figure 33: Therapy Wise Market Size of NASH in Germany, in USD Million (2016-2024)
Figure 34: Market Size of NASH in France, in USD Million (2016-2024)
Figure 35: Therapy Wise Market Size of NASH in France, in USD Million (2016-2024)
Figure 36: Market Size of NASH in the United Kingdom, in USD Million (2016-2024)
Figure 37: Therapy Wise Market Size of NASH in United Kingdom, in USD Million (2016-2024)
Figure 38: Market Size of NASH in Spain, in USD Million (2016-2024)
Figure 39: Therapy Wise Market Size of NASH in Spain, in USD Million (2016-2024)
Figure 40: Market Size of NASH in Italy, in USD Million (2016-2024)
Figure 41: Therapy Wise Market Size of NASH in Italy, in USD Million (2016-2024)
Figure 42: Market Size of NASH in Japan, in USD Million (2016-2024)
Figure 43: Therapy Wise Market Size of NASH in Japan, in USD Million (2016-2024)
Figure 44: Gilead Total Revenues in USD Billion (2014-2017)
Figure 45: Gilead Research and Development Expenses in USD Billion (2015-2017)
Figure 46: Intercept Revenue in USD Billion (2013-2017)
Figure 47: Intercept Reseach and Development Expenses in USD Billion (2013-2017)
Figure 48: Allergan Revenue in USD Billion (2013-2017)
Figure 49: Galmed Researchand Development Expenses (2015-2017)
Table 1: NASH Scoring System
Table 2: Modified Laennec Scoring System
Table 3: AALD; ASG;AGA:NASH Diagnostic Recommendation
Table 4: EASL, EASD,EASO: NASH Diagnostic Recommendation
Table 5: Evidence Grade System Used by EASL-EASD-EASO Clinical Practice Guidelines on NAFLD
Table 6: Treatment Guidelines by EASO
Table 7: Practical Guidelines by Japanese Society of Gastroenterology
Table 8: Practical Guidelines by Japanese Society of Gastroenterology
Table 9: Prevalent Cases of NASH in the United States (2016-2024)
Table 10: Sub-type Specific Prevalent Cases of NASH in the United States (2016-2024)
Table 11: Diagnosed Cases of NASH in the United States (2016-2024)
Table 12: Prevalent Cases of NASH in Germany (2016-2024)
Table 13: Sub-type Specific Prevalent Cases of NASH in the Germany (2016-2024)
Table 14: Diagnosed Cases of NASH in Germany (2016-2024)
Table 15: Prevalent Cases of NASH in France (2016-2024)
Table 16: Sub-type Specific Prevalent Cases of NASH in France (2016-2024)
Table 17: Diagnosed Cases of NASH in the France (2016-2024)
Table 18: Prevalent Cases of NASH in the United Kingdom (2016-2024)
Table 19: Sub-type Specific Prevalent Cases of NASH in United Kingdom (2016-2024)
Table 20: Diagnosed Cases of NASH in the UK (2016-2024)
Table 21: Diagnosed Cases of NASH in the Spain (2016-2024)
Table 22: Sub-type specific Cases of NASH in the Spain (2016-2024)
Table 23: Diagnosed Cases of NASH in the Spain (2016-2024)
Table 24: Prevalent Cases of NASH in the Italy (2016-2024)
Table 25: Sub-type Specific Prevalent Cases of NASH in the Italy (2016-2024)
Table 26: Diagnosed Cases of NASH in the Italy (2016-2024)
Table 27: Prevalent Cases of NASH in the Japan (2016-2024) Italy (2016-2024)
Table 28: Sub-type Specific Prevalent Cases of NASH in the Japan (2016-2024)
Table 29: Diagnosed Cases of NASH in the Japan (2016-2024)
Table 30: Major Market Size of NASH , in USD Million (2016-2024)
Table 31: Market Size of NASH in the United States, in USD Million (2016-2024)
Table 32: Therapy Wise Market Size of NASH in the United States, in USD Million (2016-2024
Table 33: Therapy Wise Market Size of NASH in Germany, in USD Million (2016-2024)
Table 34: Therapy Wise Market Size of NASH in Germany, in USD Million (2016-2024)
Table 35: Therapy Wise Market Size of NASH in France, in USD Million (2016-2024)
Table 36: Therapy Wise Market Size of NASH in France, in USD Million (2016-2024)
Table 37: Therapy Wise Market Size of NASH in the United Kingdom, in USD Million (2016-2024)
Table 38: Therapy Wise Market Size of NASH in the United Kingdom , in USD Million (2016-2024)
Table 39: Market Size of NASH in the Spain, in USD Million (2016-2024)
Table 40: Therapy Wise Market Size of NASH in the Spain , in USD Million (2016-2024)
Table 41: Market Size of NASH in the Italy , in USD Million (2016-2024)
Table 42: Therapy Wise Market Size of NASH in the Italy , in USD Million (2016-2024)
Table 43: Market Size of NASH in the Japan, in USD Million (2016-2024)
Table 44: Therapy Wise Market Size of NASH in the Japan , in USD Million (2016-2024)
Table 45: Phase III Drug Analysis for NASH
Table 46: Elafibranor Clinical Trial Description
Table 47: Cenicriviroc Clinical Trial Description
Table 48: Cenicriviroc Clinical Trial Description
Table 49: Obeticholic acid Clinical Trial Description
Table 50: Endpoints in Clinical Trials
Table 51: Gilead Product Overview